Anti-Human IL-23 (Guselkumab)

Unknown

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Guselkumab. CNTO1959 (Guselkumab) activity is directed against the p19 subunit of human IL-23.

IL-23 is a member of the IL-12 family of proinflammatory and immunoregulatory cytokines¹ and plays a key role in the differentiation and proliferation of type 17 helper T cells (Th17)². IL- 23 exists as a heterodimer composed of the IL-12p40 subunit and a novel p19 subunit that is shared with IL-39³. IL-23 activities lead to the production of Th17-derived pro-inflammatory cytokines IL-17 and IL-22¹. Additionally, IL-23 possesses potent anti-tumor and anti-metastatic activity in mouse models of cancer, suggesting a potential role for IL-23 in therapeutic treatment of cancer⁴. IL-23 also contributes to chronic inflammation of immune-mediated diseases including psoriasis and psoriatic arthritis².

Guselkumab was developed using MorphoSys proprietary HuCAL ® antibody library technology² to explore IL-23 blockade without interfering with IL-12 activity⁵. Guselkumab inhibits the biological activity of secreted IL-23 by preventing IL-23 from binding to cell surface receptors and consequently blocking the initiation of IL-23-receptor-mediated signaling.

Guselkumab has been approved for treatment of psoriasis and psoriatic arthritis. Guselkumab is also being tested for the treatment of ulcerative colitis⁶.

IL-23 is secreted by activated dendritic cells, macrophages, and monocytes.

IL12B, IL12RB1, IL23R

1 Korn T, Oukka M, Kuchroo V, et al. Semin Immunol. 19(6):362-371. 2007.
2 Markham A. Drugs. 77(13):1487-1492. 2017.
3 Deodhar A, Gottlieb AB, Boehncke WH, et al. Lancet. 391(10136):2213-2224. 2018.
4 Wertheimer T, Zwicky P, Rindlisbacher L, et al. Nat Immunol. 25(3):512-524. 2024.
5 Zhuang Y, Calderon C, Marciniak SJ Jr, et al. Eur J Clin Pharmacol. 72(11):1303-1310. 2016.
6 Hanžel J, D'Haens GR. Expert Opin Biol Ther. 20(4):399-406. 2020.
7 Sofen H, Smith S, Matheson RT, et al. J Allergy Clin Immunol. 133(4):1032-1040. 2014.
8 Blauvelt A, Papp KA, Griffiths CE, et al. J Am Acad Dermatol. 76(3):405-417. 2017.
9 Reich K, Armstrong AW, Foley P, et al. J Am Acad Dermatol. 76(3):418-431. 2017.
10 Mease PJ, Rahman P, Gottlieb AB, et al. Lancet. 395(10230):1126-1136. 2020.